Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

FARON Aktie

>FARON Performance
1 Woche: +4,5%
1 Monat: -14,3%
3 Monate: -75,1%
6 Monate: -75,0%
1 Jahr: -79,6%
laufendes Jahr: -75,1%
>FARON Aktie
Name:  FARON PHARMACEUTICALS OY
Land:  Finnland
Sektor:  Gesundheit
ISIN/ Wkn:  FI4000153309 / A14355
Symbol/ Ticker:  4FR (Frankfurt)
Kürzel:  FRA:4FR, ETR:4FR, 4FR:GR
Index:  -
Webseite:  https://www.faron.com/
Profil:  Faron Pharmaceuticals Oy is a biopharmaceutical company focused on developing novel treatments for medical conditions with significant unmet needs. Based in Finland, the company engages in extensive clinical research to bring forward innovative thera..
>Volltext..
Marktkapitalisierung:  104.78 Mio. EUR
Unternehmenswert:  117.14 Mio. EUR
Umsatz:  -
EBITDA:  -20.29 Mio. EUR
Nettogewinn:  -27.73 Mio. EUR
Gewinn je Aktie:  -0.25 EUR
Schulden:  25.11 Mio. EUR
Liquide Mittel:  12.53 Mio. EUR
Operativer Cashflow:  -24.77 Mio. EUR
Bargeldquote:  0.65
Umsatzwachstum:  -
Gewinnwachstum:  -5.16%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  FARON
Letzte Datenerhebung:  04.04.26
>FARON Kennzahlen
Aktien/ Unternehmen:
Aktien: 116.36 Mio. St.
Frei handelbar: 52.78%
Leerverk. Aktien: -
Rückkaufquote: -10.98%
Mitarbeiter: 33
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Buy
Kursziel: 610.7%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -183.59%
Eigenkaprendite: -
>FARON Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
31.03.26 - 08:30
Faron Pharmaceuticals Ltd: Director Dealing (Accesswire)
 
TURKU, FI / ACCESS Newswire / March 31, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces to......
27.03.26 - 09:12
IN BRIEF: Faron Pharmaceuticals hires Heikki Jouttijarvi as CTO (Alliance)
 
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Hires Heikki Jouttijarvi as chief technical officer...
26.03.26 - 08:30
Faron Pharmaceuticals Ltd: Faron Appoints New CTO to Strengthen Late-Stage Development Activities (Accesswire)
 
TURKU, FI / ACCESS Newswire / March 26, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company, announces the appointment of Mr. Heikki Jouttijä......
19.03.26 - 08:36
Faron Pharmaceuticals Ltd: Director Dealing (Accesswire)
 
TURKU, FI / ACCESS Newswire / March 19, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces to......
15.03.26 - 03:00
Faron Pharma Plans €40m raise for Bexmarilimab trial - ICYMI (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
14.03.26 - 14:12
Light Science Technologies, Ilika, Active Energy, Faron Pharmaceuticals, Solvonis Therapeutics, Coiled Therapeutics - Small Caps Week in Review (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
14.03.26 - 10:48
Faron Pharma Plans €40m raise for Bexmarilimab trial - ICYMI (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
13.03.26 - 17:48
Light Science, Ilika, Active Energy, Faron Pharmaceuticals, Solvonis, Coiled Therapeutics (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
12.03.26 - 20:36
Faron Pharmaceuticals CEO on €40M raise for key bexmarilimab trial (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
12.03.26 - 15:51
Faron Pharmaceuticals Ltd: Holding(s) in Company (Accesswire)
 
TURKU, FINLAND / ACCESS Newswire / March 12, 2026 / Faron Pharmaceuticals (HEL:FARON) (LSE:FARN)TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to t......
11.03.26 - 10:24
Great Southern Copper, Sunda Energy, Faron Pharmaceuticals, Astrid Intelligence, Bellevue Healthcare Trust - Small Cap Snapshot (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
10.03.26 - 11:24
Great Southern Copper, Sunda Energy, Faron Pharmaceuticals, Astrid Intelligence, Bellevue Healthcare (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
09.03.26 - 19:06
Faron Pharmaceuticals: Update to Faron′s Financial Calendar and Date of the Annual General Meeting in 2026 (Accesswire)
 
TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunot......
04.03.26 - 19:06
Faron shares soar as commercial talks on pipeline cancer drug underway (Alliance)
 
Faron Pharmaceuticals Ltd shares rose over 14% on Wednesday after the Turku, Finland-based biopharma's chief executive...
04.03.26 - 18:18
CORRECTION: Faron Pharmaceuticals Ltd′s Annual Report 2025 published (Accesswire)
 
The Annual Report 2025 published did not contain the auditor's report. This has been corrected in this version. TURKU, FINLAND / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(......
04.03.26 - 08:42
Faron Pharmaceuticals: Faron′s Financial Statements Release 1 January to 31 December 2025 (Accesswire)
 
TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Continued steady progress with bexmarilimab and solidifying position as a leading macrophage based immuno......
04.03.26 - 08:42
Faron Pharmaceuticals Ltd′s Annual Report 2025 Published (Accesswire)
 
TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, tod......
02.03.26 - 11:30
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting (Accesswire)
 
TURKU, FI / ACCESS Newswire / March 2, 2026 / Faron Pharmaceuticals Ltd (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, anno......
02.03.26 - 08:30
Faron Pharmaceuticals: Faron and City of Hope in Process of Developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS (Accesswire)
 
Building on the clinical results of the BEXMAB trial, the IIT aims to evaluate bexmarilimab with an oral HMA backbone to further strengthen evidence of its efficacy in research participants with hi......
23.02.26 - 08:30
Faron Pharmaceuticals: Faron′s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026 (Accesswire)
 
TURKU, FI / ACCESS Newswire / February 23, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherap......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!